



CORPORATE PRESENTATION • JUNE 2026

Precision AI that identifies the patients driving clinical trial success.

FDA-reviewed • Peer-reviewed (Nature portfolio) • CRO-embedded

LISTED ON

TSX: AIAI

ALSO ON

OTCQB: AINMF
FRA: PF0

IMPORTANT — PLEASE READ

Cautionary note regarding forward-looking statements.

ABOUT THIS DOCUMENT

This presentation has been prepared by NetraMark Holdings Inc. ("NetraMark" or the "Company") and contains information pertaining to the business, operations and assets of the Company. It is provided as at the date hereof and is subject to change without notice. This document does not purport to contain all information necessary to evaluate the Company and is not a recommendation to invest. Refer to filings on SEDAR+ before making any investment decision.

FORWARD-LOOKING STATEMENTS

Certain statements herein constitute forward-looking information within the meaning of applicable Canadian securities legislation, including statements about NetraAI's ability to identify subpopulations, expected commercial momentum, contracted deal value, projected revenue recognition and the outcomes of regulatory engagement. These are expectations only and are subject to risks and uncertainties; actual results may differ materially. The Company undertakes no obligation to update them except as required by law.

THIRD-PARTY DATA & U.S. NOTICE

Market data was obtained from public sources believed to be reliable; the Company has not independently verified third-party data. The securities described herein have not been registered under the U.S. Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption. In making any investment decision, investors must rely on their own examination of the Company, including the merits and risks involved.

FURTHER INFORMATION

SEDAR+ filings — [sedarplus.ca](https://www.sedarplus.ca)

Investor relations — george@netramark.com

Investor page — netramark.ai/investors

TRIAL ECONOMICS

90%


of Phase II/III trials
fail to meet primary endpoint

Source: BIO / Informa, 2010-2023

WHY TRIALS FAIL

Heterogeneous patient populations.

- 01 Hidden subpopulations**
Responders and non-responders aggregate together — the signal averages to noise.
- 02 Placebo & adverse drift**
Endpoints drift as placebo response inflates and adverse events compound.
- 03 Site & patient quality**
Bad sites and miscoded patients corrupt readouts long before analysis begins.



INTRODUCING

NetraAI™

Explainable AI that finds the patients, sites and signals that drive — or break — a clinical trial.

THREE CAPABILITIES

One platform.

01 Subpopulation discovery

Identify responder cohorts hidden in trial readouts and protect pivotal study design.

02 Placebo & adverse response

Quantify and segment placebo drift and AE clusters before they swamp the endpoint.

03 Site & patient adjudication

Flag paradoxical sites and miscoded patients to clean readouts at source.

WORKFLOW

From sponsor data to actionable trial strategy.

01

Ingest

Sponsor delivers anonymised trial readouts — biomarkers, endpoints, AEs, site metadata.

→ 02

Discover

NetraAI clusters latent subpopulations and ranks features driving response or failure.

→ 03

Explain

Every cohort, signal and adjudication call returns with a transparent, auditable rationale.

→ 04

Deploy

Recommendations feed protocol amendments, site triage and next-trial design.

Why it matters

Every output is explainable — sponsors and regulators see the why, not just the what.

EXTERNAL VALIDATION

FDA reviewed. Peer reviewed. Commercially deployed.

REGULATORY2024	SCIENTIFIC2023-2025	COMMERCIAL2025
FDA Critical Path Innovation Meeting Engaged FDA on NetraAI's role in subpopulation discovery for pivotal trial design.	Nature portfolio Peer-reviewed methodology NetraAI methodology and case results published across Nature portfolio journals.	Top-5 CRO Embedded into CRO workflow NetraAI is operationally embedded with a top-tier CRO, running against live trial data.

TRACTION — JUNE 2026

Commercial momentum is compounding.

\$24M+ 11

contracted deal value

across active sponsor and CRO engagements

11

active engagements

spanning oncology, CNS and rare disease

4

pivotal trials

in which NetraAI outputs informed protocol decisions

Pipeline coverage

Coverage now spans early Phase II readouts through pivotal Phase III reanalysis.

ACTIVE PROGRAMS

Where NetraAI is deployed today.

PROGRAM	THERAPEUTIC AREA	PHASE	ENGAGEMENT	STATUS
Sponsor A	Oncology — solid tumor	III	Subpopulation discovery	Live
Sponsor B	CNS — depression	II	Placebo response	Live
Sponsor C	Rare disease	II/III	Patient adjudication	Live
Sponsor D	Cardiometabolic	II	Site triage	Live
CRO Partner	Multi-sponsor portfolio	I–III	Embedded NetraAI	Expanding
Sponsor E	Immunology	II	Subpopulation discovery	Onboarding
Sponsor F	Oncology — heme	III	Pivotal reanalysis	Onboarding

Sponsor identities withheld under NDA; programs as of June 2026.

MARKET OPPORTUNITY

A multi-billion-dollar AI layer for clinical trials.

THREE CONCENTRIC MARKETS

TAM

\$18B

Global clinical analytics & AI software

SAM

\$6.5B

AI-driven trial optimisation & enrichment

SOM

\$650M

5-year addressable with NetraAI's wedge



Sources: Grand View Research, IQVIA, internal estimates (2026).

LEADERSHIP

Operators, scientists and capital-markets veterans.

George Achilleos

CHIEF EXECUTIVE OFFICER

Capital markets, public-company operator; leads strategy and IR.



Joseph Geraci, PhD

FOUNDER & CHIEF SCIENTIST

Mathematician; inventor of NetraAI; published in Nature portfolio.



Lucas Siow

CHIEF OPERATING OFFICER

Scaled enterprise SaaS deployments across regulated industries.



Dr. Anne Marie

CHIEF MEDICAL OFFICER

Clinical leadership across oncology, CNS and rare-disease trials.



Jeremy Mailman

CHIEF FINANCIAL OFFICER

Public-company CFO; capital structure, audit, governance.



Advisory Board

INDUSTRY & ACADEMIC

Senior leaders from FDA-adjacent academia, sponsors and CROs.



CAPITAL STRUCTURE

Tale of the tape.

Shares outstanding	91.8 million
Insider ownership	~22M shares (fully diluted)
52-week range	C\$0.68 – C\$1.10
TSX listing	AIAI
OTCQB listing	AINMF
Frankfurt listing	PF0

Source: TMX Money; market data subject to change. Sparkline shown for illustration.

TSX: AIAI • OTCQB: AINMF • FRA: PF0



WHY NOW

Three tailwinds, converging.

01

Regulatory tailwind

FDA is actively guiding sponsors on explainable AI in trial design — and we are already in the room.

02

AI inflection

Sponsors have moved from AI curiosity to procurement; budgets are landing in 2026 and 2027.

03

Commercial proof

Live revenue, embedded CRO workflow and pivotal trial wins validate the wedge.

The thesis

Explainable, regulator-grade AI is the next layer of clinical trial infrastructure. NetraAI is the wedge.

CONTACT

Let's talk.

George Achilleos

CHIEF EXECUTIVE OFFICER

george@netramark.com

+1 (289) 907-AIAI

LISTED ON

AIAI

Toronto Stock Exchange

OTCQB: AINMF • FRA: PF0

